CytoDx, a Bio Company Developing Blood-Based Cancer Precision Diagnosis Technology, Signs MOU with Gangnam Severance Hospital

Cytodix Co., Ltd. (CEO Yo-Seop Sunwoo), a specialized company in blood-based precision cancer diagnostic technology development, and Gangnam Severance Hospital of Yonsei University College of Medicine (Hospital Director Young-Koo Song) signed a strategic business agreement on August 1 to activate research on cancer precision diagnostic technology development required in clinical settings of medical institutions and to commercialize the researched technologies.

[Photo by CytoDx Co., Ltd.]

Specifically, through this business agreement, Cytodix Co., Ltd. will provide its blood-based precision cancer diagnostic technology to Gangnam Severance Hospital to develop commercial diagnostic technologies for clinical application such as companion diagnostics and early diagnosis of cancer at Gangnam Severance Hospital. Additionally, this agreement is expected to establish a close cooperative system for research and development, including the discovery of new biomarkers necessary for cancer precision diagnosis.

Cytodix Co., Ltd. is a bio venture company developing liquid biopsy technology. Liquid biopsy technology is a blood-based testing method that overcomes the limitations of conventional invasive cancer diagnostic tests involving fine needle aspiration or skin incisions. It enables companion diagnostics, early diagnosis, and early detection of metastasis/recurrence of cancer using only collected blood. This liquid biopsy technology is also recognized as the top next-generation core technology selected by the World Economic Forum (WEF) and MIT.

Cytodix Co., Ltd. is developing liquid biopsy technology that detects and analyzes circulating tumor cells (CTCs) in the blood, known as the cause of metastatic cancer, for precise cancer diagnosis. To realize this, the company is integrating automated equipment technology and analysis platform technology to develop full-cycle technologies required in clinical settings.

Currently, Cytodix has conducted over 1,000 clinical studies on patient clinical specimens of pancreatic cancer, lung cancer, thyroid cancer, and breast cancer at four leading university hospitals in Korea, including Gangnam Severance Hospital, Bundang Seoul National University Hospital, and Korea University Guro Hospital, verifying clinical efficacy. Furthermore, to utilize the vast data built through specimen validation for various purposes, the company is developing an AI analysis platform.

Yo-Seop Sunwoo, CEO of Cytodix Co., Ltd., stated, “Through this business agreement, we will achieve the goal of commercialization by expanding clinical research on various cancer types and completing the Ministry of Food and Drug Safety approval and new medical technology evaluation for circulating tumor cell-based companion diagnostic technology. We are also coordinating with multiple clinical institutions to expand the development of diagnostic technologies tailored to the purpose and timing of diagnosis for various cancer types.”

This content was produced with the assistance of AI translation services.